Spotlight
Topic
Brand Insights
Subscribe
- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
UK Pharma Companies Face £45 million in Pay-For-Delay Deal Fines
February 22, 2016.
The Competition and Markets Authority (CMA), a UK-based non-ministerial department monitoring market competition, has fined multiple pharmaceutical companies £45 million ($64.3 million) for pay-for-delay deals.
CMA says these deals “potentially deprived the National Health Service of the significant price falls that generally result from generic competition.” Chapter I prohibition of the Competition Act of 1998 prohibits these methods of competition restriction. A company found in violation of this act can face fines of up to 10% of its worldwide turnover.
See more on this story here at Pharmaceutical Technology.
Recent Videos
Related Content
